<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248650</url>
  </required_header>
  <id_info>
    <org_study_id>TRK-820_HD_I_2008</org_study_id>
    <nct_id>NCT01248650</nct_id>
  </id_info>
  <brief_title>Safety Study of TRK-820 for Patient With Hemodialysis</brief_title>
  <acronym>TRK-820</acronym>
  <official_title>A Clinical Study to Investigate Pharmacokinetics and Safety of Single-Dose TRK-820 Soft Capsule in Patient With Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toray Industries, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe pharmacokinetics and safety of nalfurafine
      hydrochloride in patients receiving hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>TRK-820 5 μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking TRK-820 5μg(two 2.5μg soft capsules) once on the first day of hospitalization by oral route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRK-820 2.5μg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taking TRK-820 2.5μg(one 2.5μg soft capsule) once on the first day of hospitalization by oral route</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalfurafine hydrochloride</intervention_name>
    <arm_group_label>TRK-820 5 μg</arm_group_label>
    <arm_group_label>TRK-820 2.5μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic renal failure who receive dialysis three times a week on a
             regular basis and do not expect an important change in treatment nor a rapid change in
             conditions

          -  Patients aged 20 years or older

          -  Patients whose post-dialysis BMI measured at the nearest time before the singing day
             is in the range of 70 ~ 130 %

          -  Patients who can understand and follow instructions and participate in the study
             during the entire study period

          -  Patients who signed the informed consent form before participating in the study

        Exclusion Criteria:

          -  Patients who have confirmed malignant tumor

          -  Patients with cognitive impairment including depression, schizophrenia and dementia

          -  Patients with hepatic cirrhosis as a complication

          -  Patients with drug allergy to opioids

          -  Patients with drug dependency or allergic disease (including skin response to UV
             radiation)

          -  Patients who participated in other study and received the investigational drug within
             1 month before the signing day

          -  Patients who participated in other TRK-820 study within 4 weeks before the signing day

          -  Pregnant or lactating women or premenopausal women of childbearing potential who do
             not conduct contraception

          -  Patients who received any of the following drugs within 2 weeks before Day 1

               1. Azole antifungal agents

                    1. Ketoconazole

                    2. Fluconazole

                    3. Itraconazole

                    4. Clotrimazole

               2. Macrolide antibiotics

                    1. Erythromycin

                    2. Midecamycin

                    3. Josamycin

                    4. Roxithromycin

                    5. Clarithromycin

                    6. Triacetyloleandomycin

               3. Ritonavir

               4. Cyclosporine

               5. Nifedipine

               6. Cimetidine

               7. Amiodarone

          -  Patients who had the following drinks and foods within 2 weeks before Day 1

               1. Foods and drinks containing grape fruit juice

               2. Food and drinks containing St. John's wort

          -  Patients who participated in other clinical study during the period between the
             singing day and hospitalization (Day 1)

          -  Patients who smoked and drank from three months before the signing day

          -  Patients who are ineligible for the clinical study for other reasons at the
             investigator's discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wooseong Huh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>November 24, 2010</last_update_submitted>
  <last_update_submitted_qc>November 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hogan Park</name_title>
    <organization>SK Chemicals Co.,Ltd.</organization>
  </responsible_party>
  <keyword>Safety evaluation</keyword>
  <keyword>Pharmacokinetic analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

